About us Pricing ContactSubscribe

M

M. Pérol

Centre de Recherche en Cancérologie de LyonORCID https://orcid.org/0000-0002-3296-423X

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

The Lancet Oncology20211,333 citations

M. Pérol · Scinovex